FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Novel Pediatrics/Neonatology Drugs in Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Samarium Sm-153

            Therapeutic Area: Pediatrics/Neonatology

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Q2Earth

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 22, 2020

            Details:

            Q2Earth has signed an Exclusive Dealing Option Agreement with IGL Pharma to potentially execute a worldwide, exclusive license agreement for the radiopharmaceutical Samarium-153 DOTMP .